United Capital Financial Advisors LLC Lowers Holdings in Stryker Co. (NYSE:SYK)

United Capital Financial Advisors LLC reduced its stake in Stryker Co. (NYSE:SYK - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,908 shares of the medical technology company's stock after selling 15,399 shares during the period. United Capital Financial Advisors LLC's holdings in Stryker were worth $19,770,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. J. W. Coons Advisors LLC raised its stake in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC increased its holdings in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after acquiring an additional 27 shares in the last quarter. Opal Wealth Advisors LLC raised its position in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after purchasing an additional 28 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares in the last quarter. Finally, Alhambra Investment Management LLC grew its position in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Barclays increased their price objective on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $423.53.

Stryker Trading Down 0.1 %

Stryker stock traded down $0.21 during trading hours on Friday, reaching $346.46. The company had a trading volume of 1,349,873 shares, compared to its average volume of 1,359,832. The company has a 50-day moving average price of $370.95 and a 200 day moving average price of $373.04. The firm has a market cap of $132.24 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 EPS. Equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.97%. Stryker's payout ratio is 43.30%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.